Skip to main content

Erosive Esophagitis

9
Pipeline Programs
10
Companies
13
Clinical Trials
1 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
6
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
3100%
+ 13 programs with unclassified modality

On Market (2)

Approved therapies currently available

AstraZeneca
NEXIUMApproved
esomeprazole magnesium
AstraZeneca
oral2001
74M Part D
AstraZeneca
NEXIUM 24HRApproved
esomeprazole magnesium
AstraZeneca
oral2015

Competitive Landscape

10 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
4 programs
1
3
EsomeprazolePhase 4Small Molecule1 trial
EsomeprazolePhase 4Small Molecule1 trial
esomeprazole magnesiumPhase 41 trial
Nexium 20mgPhase 31 trial
Active Trials
NCT05267613Active Not Recruiting53Est. Aug 2026
NCT00644735Completed750Est. Jan 2004
NCT00641602Completed1,000Est. Aug 2003
+1 more trials
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
1
Omeprazole/sodium bicarbonatePhase 41 trial
Active Trials
NCT00693225Completed91Est. Dec 2010
Onconic Therapeutics
1 program
1
JP-1366 20mgPhase 31 trial
Active Trials
NCT05443984Completed300Est. Jan 2023
Yooyoung Pharmaceutical
Yooyoung PharmaceuticalKorea - Jincheon
1 program
1
YYD601 40mgPhase 31 trial
Active Trials
NCT03943992Completed170Est. Jul 2020
Phathom Pharmaceuticals
Phathom PharmaceuticalsFLORHAM PARK, NJ
3 programs
VonoprazanN/A1 trial
VonoprazanPHASE_11 trial
VonoprazanPHASE_31 trial
Active Trials
NCT06660342Recruiting728Est. Sep 2034
NCT06391177Completed15Est. Sep 2024
NCT04124926Completed1,027Est. Aug 2021
Takeda
TakedaTOKYO, Japan
2 programs
DexlansoprazolePHASE_3Small Molecule1 trial
VonoprazanPHASE_41 trial
Active Trials
NCT02873702Terminated37Est. Nov 2017
NCT02679508Completed208Est. Mar 2022
Cinclus Pharma
Cinclus PharmaSweden - Stockholm
1 program
X842PHASE_21 trial
Active Trials
NCT05055128Completed248Est. Sep 2022
Parexel
ParexelMA - Boston
1 program
X842PHASE_2
Thermo Fisher Scientific
1 program
Nexium 20mgPHASE_3
IQVIA
IQVIADURHAM, NC
1 program
Nexium 20mgPHASE_3

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
TakedaVonoprazan
Bausch HealthOmeprazole/sodium bicarbonate
AstraZenecaesomeprazole magnesium
AstraZenecaEsomeprazole
AstraZenecaEsomeprazole
AstraZenecaNexium 20mg
Onconic TherapeuticsJP-1366 20mg
Phathom PharmaceuticalsVonoprazan
Yooyoung PharmaceuticalYYD601 40mg
TakedaDexlansoprazole
Cinclus PharmaX842
Phathom PharmaceuticalsVonoprazan
Phathom PharmaceuticalsVonoprazan

Clinical Trials (13)

Total enrollment: 4,747 patients across 13 trials

Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety

Start: Mar 2016Est. completion: Mar 2022208 patients
Phase 4Completed
NCT00693225Bausch HealthOmeprazole/sodium bicarbonate

Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study

Start: Jan 2008Est. completion: Dec 201091 patients
Phase 4Completed
NCT00206180AstraZenecaesomeprazole magnesium

NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis

Start: Jun 2004Est. completion: Aug 2005120 patients
Phase 4Completed

A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis

Start: Dec 2002Est. completion: Aug 20031,000 patients
Phase 4Completed

Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed

Start: Dec 2002Est. completion: Jan 2004750 patients
Phase 4Completed

Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.

Start: Jul 2022Est. completion: Aug 202653 patients
Phase 3Active Not Recruiting

JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis

Start: Jan 2022Est. completion: Jan 2023300 patients
Phase 3Completed

Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis

Start: Oct 2019Est. completion: Aug 20211,027 patients
Phase 3Completed

Clinical Trial to Assess the Efficacy and Safety of YYD601 in the Treatment of Esophageal Reflux Disease (ERD)

Start: Jan 2019Est. completion: Jul 2020170 patients
Phase 3Completed
NCT02873702TakedaDexlansoprazole

Efficacy and Safety of Dexlansoprazole in Healing and Maintaining Healing of Erosive Esophagitis

Start: Dec 2016Est. completion: Nov 201737 patients
Phase 3Terminated

A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole

Start: Aug 2021Est. completion: Sep 2022248 patients
Phase 2Completed

A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily

Start: May 2024Est. completion: Sep 202415 patients
Phase 1Completed

A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring

Start: May 2025Est. completion: Sep 2034728 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 4,747 patients
10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.